Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
The company plans to invest the money across several therapeutic areas and modalities, including oncology, immunology, gene and cell therapies.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
It was reported earlier this week in The Wall Street Journal that, while an IPO without the SEC signing off is allowed with a certain workaround, it is carries legal and regulatory risks.
The report also showed 1H18 VC funding already nearly equaled investment in 2017. That's consistent with Silicon Valley Bank's findings on Series A rounds last month.